Project Portfolio
The inflamed pharma GmbH was founded in 2019 and is based in Jena. inflamed pharma is a manufacturer of pharmaceutical active ingredients used in innovative therapies for human and veterinary medicine.
With JenClutec®, the company has developed a technology that specifically optimizes the properties of active substances - particularly their solubility - while enabling formulation into a wide range of dosage forms. To date, JenClutec® has already been used to improve 30 different substances. The company offers its technology as a service to pharmaceutical and biotechnology companies.
Inventum Genetics GmbH was incorporated in 2019 in Mainz, Germany.
Inventum Genetics GmbH is dedicated to identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. To this end, the company collaborates with the Center for Human Genetics at the Philipps University of Marburg (Germany). The focus is on the genetic analysis of biological processes. The first project deals with the cellular response to DNA damage, a central mechanism of neurodegenerative and oncological diseases. The global market for drugs targeting DNA repair mechanisms is expected to reach $25 billion by 2030.
The palleos healthcare GmbH was incorporated in 2013 based in Wiesbaden, Germany.
Palleos healthcare GmbH is a full-service company ("CRO") for clinical research. In this role, the company offers a wide range of services, from clinical development to study completion. The company's goal is to bridge the regulatory and operational gap between preclinical and clinical development to implement innovative concepts for its clients. Due to numerous partnerships, palleos healthcare can also offer its services internationally.
In December 2020, Veraxa Biotech AG was founded in Zurich, Switzerland, to acquire Araxa Biosciences GmbH and Velabs Therapeutics GmbH, both based in Heidelberg, Germany.
Veraxa Biotech AG focuses on the development of antibody-drug conjugates through an innovative click chemistry approach and the microfluidic screening of functional antibodies. The portfolio ranges from early-stage projects to those in the clinical phase.
By integrating the newly added BiTAC platform into its existing technology portfolio, VERAXA is able to address the challenges of antibody‑based cancer therapies. Preclinical studies have already demonstrated the potential of the technology, which is planned to be translated into the clinical phase as the next step.
